214 related articles for article (PubMed ID: 35817022)
1. Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study.
Posch MG; Walther N; Ferrannini E; Powell DR; Banks P; Wason S; Dahmen R
Diabetes Care; 2022 Sep; 45(9):2118-2126. PubMed ID: 35817022
[TBL] [Abstract][Full Text] [Related]
2. The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery.
Martinussen C; Veedfald S; Dirksen C; Bojsen-Møller KN; Svane MS; Wewer Albrechtsen NJ; van Hall G; Kristiansen VB; Fenger M; Holst JJ; Madsbad S
Am J Physiol Endocrinol Metab; 2020 Jun; 318(6):E956-E964. PubMed ID: 32182123
[TBL] [Abstract][Full Text] [Related]
3. Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
Powell DR; Zambrowicz B; Morrow L; Beysen C; Hompesch M; Turner S; Hellerstein M; Banks P; Strumph P; Lapuerta P
J Clin Endocrinol Metab; 2020 Apr; 105(4):e1235-49. PubMed ID: 31837264
[TBL] [Abstract][Full Text] [Related]
4. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.
Powell DR; Smith M; Greer J; Harris A; Zhao S; DaCosta C; Mseeh F; Shadoan MK; Sands A; Zambrowicz B; Ding ZM
J Pharmacol Exp Ther; 2013 May; 345(2):250-9. PubMed ID: 23487174
[TBL] [Abstract][Full Text] [Related]
5. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.
Zambrowicz B; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Boehm KA; Ruff D; Powell D; Sands A
Clin Ther; 2013 Aug; 35(8):1162-1173.e8. PubMed ID: 23911260
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
Duan XY; Liu SY; Yin DG
Medicine (Baltimore); 2021 Jul; 100(30):e26431. PubMed ID: 34397684
[TBL] [Abstract][Full Text] [Related]
7. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Lapuerta P; Zambrowicz B; Strumph P; Sands A
Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
[TBL] [Abstract][Full Text] [Related]
8. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
[TBL] [Abstract][Full Text] [Related]
9. Sotagliflozin as a potential treatment for type 2 diabetes mellitus.
Cariou B; Charbonnel B
Expert Opin Investig Drugs; 2015; 24(12):1647-56. PubMed ID: 26548423
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sotagliflozin in treating diabetes type 1.
Rendell MS
Expert Opin Pharmacother; 2018 Feb; 19(3):307-315. PubMed ID: 29212386
[TBL] [Abstract][Full Text] [Related]
11. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Sands AT; Zambrowicz BP; Rosenstock J; Lapuerta P; Bode BW; Garg SK; Buse JB; Banks P; Heptulla R; Rendell M; Cefalu WT; Strumph P
Diabetes Care; 2015 Jul; 38(7):1181-8. PubMed ID: 26049551
[TBL] [Abstract][Full Text] [Related]
12. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
Cefalo CMA; Cinti F; Moffa S; Impronta F; Sorice GP; Mezza T; Pontecorvi A; Giaccari A
Cardiovasc Diabetol; 2019 Feb; 18(1):20. PubMed ID: 30819210
[TBL] [Abstract][Full Text] [Related]
13. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
[TBL] [Abstract][Full Text] [Related]
14. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
[TBL] [Abstract][Full Text] [Related]
15. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
[TBL] [Abstract][Full Text] [Related]
16. SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans.
Chae H; Augustin R; Gatineau E; Mayoux E; Bensellam M; Antoine N; Khattab F; Lai BK; Brusa D; Stierstorfer B; Klein H; Singh B; Ruiz L; Pieper M; Mark M; Herrera PL; Gribble FM; Reimann F; Wojtusciszyn A; Broca C; Rita N; Piemonti L; Gilon P
Mol Metab; 2020 Dec; 42():101071. PubMed ID: 32896668
[TBL] [Abstract][Full Text] [Related]
17. Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus.
Sims H; Smith KH; Bramlage P; Minguet J
Diabet Med; 2018 Aug; 35(8):1037-1048. PubMed ID: 29637608
[TBL] [Abstract][Full Text] [Related]
18. Study design and rationale of a dose-ranging trial of LX4211, a dual inhibitor of SGLT1 and SGLT2, in type 2 diabetes inadequately controlled on metformin monotherapy.
Lapuerta P; Rosenstock J; Zambrowicz B; Powell DR; Ogbaa I; Freiman J; Cefalu WT; Banks P; Frazier K; Kelly M; Sands A
Clin Cardiol; 2013 Jul; 36(7):367-71. PubMed ID: 23630033
[TBL] [Abstract][Full Text] [Related]
19. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Danne T; Cariou B; Buse JB; Garg SK; Rosenstock J; Banks P; Kushner JA; McGuire DK; Peters AL; Sawhney S; Strumph P
Diabetes Care; 2019 May; 42(5):919-930. PubMed ID: 30833371
[TBL] [Abstract][Full Text] [Related]
20. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
Danne T; Biester T; Kordonouri O
Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
